nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—CYP3A4—Temozolomide—malignant glioma	0.314	1	CbGbCtD
Salmeterol—Cushing's syndrome—Carmustine—malignant glioma	0.0379	0.0869	CcSEcCtD
Salmeterol—Oral candidiasis—Carmustine—malignant glioma	0.0136	0.0311	CcSEcCtD
Salmeterol—Oral candidiasis—Temozolomide—malignant glioma	0.0131	0.03	CcSEcCtD
Salmeterol—Endocrine disorder—Temozolomide—malignant glioma	0.01	0.023	CcSEcCtD
Salmeterol—Viral infection—Temozolomide—malignant glioma	0.00921	0.0211	CcSEcCtD
Salmeterol—Neck pain—Carmustine—malignant glioma	0.00871	0.02	CcSEcCtD
Salmeterol—Musculoskeletal pain—Temozolomide—malignant glioma	0.00842	0.0193	CcSEcCtD
Salmeterol—Candida infection—Carmustine—malignant glioma	0.00822	0.0188	CcSEcCtD
Salmeterol—Candida infection—Temozolomide—malignant glioma	0.00794	0.0182	CcSEcCtD
Salmeterol—Swelling—Carmustine—malignant glioma	0.00708	0.0162	CcSEcCtD
Salmeterol—Ear pain—Temozolomide—malignant glioma	0.00708	0.0162	CcSEcCtD
Salmeterol—Gastroenteritis—Temozolomide—malignant glioma	0.00681	0.0156	CcSEcCtD
Salmeterol—Injury—Carmustine—malignant glioma	0.0068	0.0156	CcSEcCtD
Salmeterol—Nasal congestion—Temozolomide—malignant glioma	0.00663	0.0152	CcSEcCtD
Salmeterol—Bronchitis—Temozolomide—malignant glioma	0.00502	0.0115	CcSEcCtD
Salmeterol—Hyperglycaemia—Carmustine—malignant glioma	0.00487	0.0112	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00485	0.0111	CcSEcCtD
Salmeterol—Pneumonia—Carmustine—malignant glioma	0.00484	0.0111	CcSEcCtD
Salmeterol—Hyperglycaemia—Temozolomide—malignant glioma	0.00471	0.0108	CcSEcCtD
Salmeterol—Urinary tract infection—Carmustine—malignant glioma	0.00468	0.0107	CcSEcCtD
Salmeterol—Pneumonia—Temozolomide—malignant glioma	0.00468	0.0107	CcSEcCtD
Salmeterol—Infestation NOS—Temozolomide—malignant glioma	0.00465	0.0107	CcSEcCtD
Salmeterol—Infestation—Temozolomide—malignant glioma	0.00465	0.0107	CcSEcCtD
Salmeterol—Urinary tract infection—Temozolomide—malignant glioma	0.00452	0.0104	CcSEcCtD
Salmeterol—Sinusitis—Temozolomide—malignant glioma	0.00437	0.01	CcSEcCtD
Salmeterol—Connective tissue disorder—Carmustine—malignant glioma	0.00425	0.00974	CcSEcCtD
Salmeterol—Pharyngitis—Temozolomide—malignant glioma	0.00415	0.0095	CcSEcCtD
Salmeterol—Connective tissue disorder—Temozolomide—malignant glioma	0.00411	0.00941	CcSEcCtD
Salmeterol—Cardiac disorder—Temozolomide—malignant glioma	0.00388	0.00889	CcSEcCtD
Salmeterol—Arrhythmia—Carmustine—malignant glioma	0.00386	0.00885	CcSEcCtD
Salmeterol—Mental disorder—Carmustine—malignant glioma	0.00379	0.00868	CcSEcCtD
Salmeterol—Immune system disorder—Temozolomide—malignant glioma	0.00377	0.00865	CcSEcCtD
Salmeterol—Mediastinal disorder—Temozolomide—malignant glioma	0.00377	0.00863	CcSEcCtD
Salmeterol—Malnutrition—Carmustine—malignant glioma	0.00376	0.00863	CcSEcCtD
Salmeterol—Mental disorder—Temozolomide—malignant glioma	0.00366	0.00839	CcSEcCtD
Salmeterol—Back pain—Carmustine—malignant glioma	0.00364	0.00834	CcSEcCtD
Salmeterol—Malnutrition—Temozolomide—malignant glioma	0.00364	0.00834	CcSEcCtD
Salmeterol—Tremor—Carmustine—malignant glioma	0.00353	0.00808	CcSEcCtD
Salmeterol—Back pain—Temozolomide—malignant glioma	0.00352	0.00806	CcSEcCtD
Salmeterol—Agitation—Carmustine—malignant glioma	0.00346	0.00793	CcSEcCtD
Salmeterol—Tremor—Temozolomide—malignant glioma	0.00341	0.00781	CcSEcCtD
Salmeterol—Ill-defined disorder—Temozolomide—malignant glioma	0.00337	0.00773	CcSEcCtD
Salmeterol—Agitation—Temozolomide—malignant glioma	0.00334	0.00766	CcSEcCtD
Salmeterol—Angioedema—Temozolomide—malignant glioma	0.00332	0.00762	CcSEcCtD
Salmeterol—Malaise—Temozolomide—malignant glioma	0.00328	0.00752	CcSEcCtD
Salmeterol—Hypertension—Carmustine—malignant glioma	0.00325	0.00745	CcSEcCtD
Salmeterol—Palpitations—Temozolomide—malignant glioma	0.00321	0.00737	CcSEcCtD
Salmeterol—Chest pain—Carmustine—malignant glioma	0.0032	0.00734	CcSEcCtD
Salmeterol—Myalgia—Carmustine—malignant glioma	0.0032	0.00734	CcSEcCtD
Salmeterol—Anxiety—Carmustine—malignant glioma	0.00319	0.00732	CcSEcCtD
Salmeterol—Cough—Temozolomide—malignant glioma	0.00317	0.00727	CcSEcCtD
Salmeterol—Hypertension—Temozolomide—malignant glioma	0.00314	0.0072	CcSEcCtD
Salmeterol—Myalgia—Temozolomide—malignant glioma	0.0031	0.0071	CcSEcCtD
Salmeterol—Arthralgia—Temozolomide—malignant glioma	0.0031	0.0071	CcSEcCtD
Salmeterol—Anxiety—Temozolomide—malignant glioma	0.00309	0.00707	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00308	0.00705	CcSEcCtD
Salmeterol—Oedema—Carmustine—malignant glioma	0.00307	0.00704	CcSEcCtD
Salmeterol—Discomfort—Temozolomide—malignant glioma	0.00306	0.00701	CcSEcCtD
Salmeterol—Infection—Carmustine—malignant glioma	0.00305	0.00699	CcSEcCtD
Salmeterol—Dry mouth—Temozolomide—malignant glioma	0.00303	0.00694	CcSEcCtD
Salmeterol—Tachycardia—Carmustine—malignant glioma	0.003	0.00687	CcSEcCtD
Salmeterol—Anaphylactic shock—Temozolomide—malignant glioma	0.00297	0.0068	CcSEcCtD
Salmeterol—Oedema—Temozolomide—malignant glioma	0.00297	0.0068	CcSEcCtD
Salmeterol—Infection—Temozolomide—malignant glioma	0.00295	0.00676	CcSEcCtD
Salmeterol—Nervous system disorder—Temozolomide—malignant glioma	0.00291	0.00667	CcSEcCtD
Salmeterol—Skin disorder—Temozolomide—malignant glioma	0.00288	0.00661	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Carmustine—malignant glioma	0.0028	0.00641	CcSEcCtD
Salmeterol—Insomnia—Carmustine—malignant glioma	0.00278	0.00637	CcSEcCtD
Salmeterol—Paraesthesia—Carmustine—malignant glioma	0.00276	0.00632	CcSEcCtD
Salmeterol—Dyspnoea—Carmustine—malignant glioma	0.00274	0.00628	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.0027	0.0062	CcSEcCtD
Salmeterol—Insomnia—Temozolomide—malignant glioma	0.00268	0.00615	CcSEcCtD
Salmeterol—Paraesthesia—Temozolomide—malignant glioma	0.00267	0.00611	CcSEcCtD
Salmeterol—Dyspnoea—Temozolomide—malignant glioma	0.00265	0.00607	CcSEcCtD
Salmeterol—Constipation—Carmustine—malignant glioma	0.00263	0.00602	CcSEcCtD
Salmeterol—Pain—Carmustine—malignant glioma	0.00263	0.00602	CcSEcCtD
Salmeterol—Dyspepsia—Temozolomide—malignant glioma	0.00261	0.00599	CcSEcCtD
Salmeterol—Fatigue—Temozolomide—malignant glioma	0.00256	0.00587	CcSEcCtD
Salmeterol—Pain—Temozolomide—malignant glioma	0.00254	0.00582	CcSEcCtD
Salmeterol—Constipation—Temozolomide—malignant glioma	0.00254	0.00582	CcSEcCtD
Salmeterol—Feeling abnormal—Carmustine—malignant glioma	0.00253	0.0058	CcSEcCtD
Salmeterol—Gastrointestinal pain—Carmustine—malignant glioma	0.00251	0.00576	CcSEcCtD
Salmeterol—Feeling abnormal—Temozolomide—malignant glioma	0.00245	0.00561	CcSEcCtD
Salmeterol—Abdominal pain—Carmustine—malignant glioma	0.00243	0.00557	CcSEcCtD
Salmeterol—Body temperature increased—Carmustine—malignant glioma	0.00243	0.00557	CcSEcCtD
Salmeterol—Gastrointestinal pain—Temozolomide—malignant glioma	0.00243	0.00556	CcSEcCtD
Salmeterol—Urticaria—Temozolomide—malignant glioma	0.00236	0.0054	CcSEcCtD
Salmeterol—Abdominal pain—Temozolomide—malignant glioma	0.00235	0.00538	CcSEcCtD
Salmeterol—Body temperature increased—Temozolomide—malignant glioma	0.00235	0.00538	CcSEcCtD
Salmeterol—Hypersensitivity—Carmustine—malignant glioma	0.00226	0.00519	CcSEcCtD
Salmeterol—Asthenia—Carmustine—malignant glioma	0.0022	0.00505	CcSEcCtD
Salmeterol—Hypersensitivity—Temozolomide—malignant glioma	0.00219	0.00501	CcSEcCtD
Salmeterol—Asthenia—Temozolomide—malignant glioma	0.00213	0.00488	CcSEcCtD
Salmeterol—Diarrhoea—Carmustine—malignant glioma	0.0021	0.00482	CcSEcCtD
Salmeterol—Dizziness—Carmustine—malignant glioma	0.00203	0.00466	CcSEcCtD
Salmeterol—Diarrhoea—Temozolomide—malignant glioma	0.00203	0.00465	CcSEcCtD
Salmeterol—Dizziness—Temozolomide—malignant glioma	0.00196	0.0045	CcSEcCtD
Salmeterol—Vomiting—Carmustine—malignant glioma	0.00195	0.00448	CcSEcCtD
Salmeterol—Rash—Carmustine—malignant glioma	0.00194	0.00444	CcSEcCtD
Salmeterol—Dermatitis—Carmustine—malignant glioma	0.00193	0.00443	CcSEcCtD
Salmeterol—Headache—Carmustine—malignant glioma	0.00192	0.00441	CcSEcCtD
Salmeterol—Vomiting—Temozolomide—malignant glioma	0.00189	0.00433	CcSEcCtD
Salmeterol—Rash—Temozolomide—malignant glioma	0.00187	0.00429	CcSEcCtD
Salmeterol—Dermatitis—Temozolomide—malignant glioma	0.00187	0.00429	CcSEcCtD
Salmeterol—Headache—Temozolomide—malignant glioma	0.00186	0.00426	CcSEcCtD
Salmeterol—Nausea—Carmustine—malignant glioma	0.00182	0.00418	CcSEcCtD
Salmeterol—Nausea—Temozolomide—malignant glioma	0.00176	0.00404	CcSEcCtD
Salmeterol—CYP2C8—Biological oxidations—CYP2C18—malignant glioma	0.000694	0.00278	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—CYP2C18—malignant glioma	0.000685	0.00274	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—GSTT1—malignant glioma	0.000648	0.0026	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—RTEL1—malignant glioma	0.000629	0.00252	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—GSTP1—malignant glioma	0.000622	0.00249	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—GSTP1—malignant glioma	0.000613	0.00245	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR3—malignant glioma	0.000612	0.00245	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—PTGS1—malignant glioma	0.000608	0.00243	CbGpPWpGaD
Salmeterol—CYP3A4—Tryptophan metabolism—CAT—malignant glioma	0.000584	0.00234	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—GSTT1—malignant glioma	0.000562	0.00225	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—BDKRB2—malignant glioma	0.000559	0.00224	CbGpPWpGaD
Salmeterol—CYP2C8—Arachidonic acid metabolism—PTGS2—malignant glioma	0.000542	0.00217	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—CCR4—malignant glioma	0.000537	0.00215	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.000532	0.00213	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—PTGS1—malignant glioma	0.000526	0.00211	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR3—malignant glioma	0.000524	0.0021	CbGpPWpGaD
Salmeterol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	0.000503	0.00201	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—BDKRB2—malignant glioma	0.000479	0.00192	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LATS2—malignant glioma	0.000459	0.00184	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—RTEL1—malignant glioma	0.000454	0.00182	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—GSTP1—malignant glioma	0.000449	0.0018	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—GSTP1—malignant glioma	0.000443	0.00177	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—KNG1—malignant glioma	0.000436	0.00175	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP2B6—malignant glioma	0.00043	0.00172	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP2B6—malignant glioma	0.000424	0.0017	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—CXCR3—malignant glioma	0.000399	0.0016	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—RTEL1—malignant glioma	0.000394	0.00158	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—GSTP1—malignant glioma	0.000389	0.00156	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—GSTP1—malignant glioma	0.000384	0.00154	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP2C18—malignant glioma	0.000373	0.00149	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP2C18—malignant glioma	0.000368	0.00147	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—BDKRB2—malignant glioma	0.000365	0.00146	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—COX8A—malignant glioma	0.000361	0.00145	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LATS1—malignant glioma	0.000348	0.00139	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—KNG1—malignant glioma	0.000332	0.00133	CbGpPWpGaD
Salmeterol—CYP3A4—Tryptophan metabolism—MDM2—malignant glioma	0.000322	0.00129	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ASMT—malignant glioma	0.000307	0.00123	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CCR4—malignant glioma	0.000303	0.00121	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—GSTT1—malignant glioma	0.000301	0.00121	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—BCAN—malignant glioma	0.000289	0.00116	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—PTGS1—malignant glioma	0.000282	0.00113	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—F2—malignant glioma	0.000282	0.00113	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	0.000281	0.00113	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CCR4—malignant glioma	0.000276	0.0011	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	0.000272	0.00109	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—COX8A—malignant glioma	0.000261	0.00104	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MDK—malignant glioma	0.000235	0.00094	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—IDH2—malignant glioma	0.000233	0.000931	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—COX8A—malignant glioma	0.000226	0.000905	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CXCR3—malignant glioma	0.000225	0.000903	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—DTX1—malignant glioma	0.000224	0.000897	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ASMT—malignant glioma	0.000222	0.000888	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP2B6—malignant glioma	0.000219	0.000876	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—F2—malignant glioma	0.000215	0.000859	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—RTEL1—malignant glioma	0.000211	0.000846	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—GSTP1—malignant glioma	0.000209	0.000836	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—BCAN—malignant glioma	0.000209	0.000835	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—BDKRB2—malignant glioma	0.000206	0.000826	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—GSTP1—malignant glioma	0.000206	0.000825	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CXCR3—malignant glioma	0.000205	0.00082	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	0.000202	0.000809	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—IDH1—malignant glioma	0.0002	0.000801	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—malignant glioma	0.000199	0.000795	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—SPHK1—malignant glioma	0.000194	0.000775	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ASMT—malignant glioma	0.000192	0.000769	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP2C18—malignant glioma	0.00019	0.000759	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	0.000188	0.000752	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—KNG1—malignant glioma	0.000188	0.000751	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—BDKRB2—malignant glioma	0.000187	0.00075	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—BCAN—malignant glioma	0.000181	0.000723	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SUFU—malignant glioma	0.000178	0.000712	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HEY2—malignant glioma	0.000176	0.000704	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GFAP—malignant glioma	0.000172	0.000687	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—KNG1—malignant glioma	0.00017	0.000682	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—IDH2—malignant glioma	0.000168	0.000673	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SPHK1—malignant glioma	0.000166	0.000665	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HEY1—malignant glioma	0.000163	0.000652	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCR4—malignant glioma	0.000163	0.000652	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HIST1H3B—malignant glioma	0.000158	0.000633	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP2B6—malignant glioma	0.000158	0.000633	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTT1—malignant glioma	0.000153	0.000614	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—CXCL8—malignant glioma	0.000151	0.000605	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—MMP3—malignant glioma	0.000151	0.000604	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—IDH2—malignant glioma	0.000146	0.000583	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—IDH1—malignant glioma	0.000145	0.000579	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—JAG2—malignant glioma	0.000144	0.000578	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTGS1—malignant glioma	0.000144	0.000575	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SPHK1—malignant glioma	0.00014	0.00056	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	0.000137	0.00055	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP2C18—malignant glioma	0.000137	0.000549	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2B6—malignant glioma	0.000137	0.000548	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—BCHE—malignant glioma	0.000134	0.000535	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—SLC5A5—malignant glioma	0.000132	0.000528	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—IDH1—malignant glioma	0.000125	0.000501	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—H3F3A—malignant glioma	0.000122	0.000489	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—COX8A—malignant glioma	0.000121	0.000486	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—F2—malignant glioma	0.000121	0.000486	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SPHK1—malignant glioma	0.000121	0.000485	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCR3—malignant glioma	0.000121	0.000484	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2C18—malignant glioma	0.000119	0.000475	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NTRK2—malignant glioma	0.000118	0.000471	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—YWHAE—malignant glioma	0.000118	0.000471	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FLT1—malignant glioma	0.000117	0.000469	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—DUSP6—malignant glioma	0.000117	0.000467	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CG—malignant glioma	0.000116	0.000465	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—JAG1—malignant glioma	0.000115	0.000461	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOTCH3—malignant glioma	0.000115	0.000459	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FBXW7—malignant glioma	0.000113	0.000452	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	0.000112	0.000448	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTT1—malignant glioma	0.000111	0.000444	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—BDKRB2—malignant glioma	0.000111	0.000443	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—F2—malignant glioma	0.00011	0.000441	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTP1—malignant glioma	0.000106	0.000426	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKT2—malignant glioma	0.000106	0.000425	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CG—malignant glioma	0.000105	0.000422	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTGS1—malignant glioma	0.000104	0.000416	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PTPN11—malignant glioma	0.000104	0.000415	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CAT—malignant glioma	0.000103	0.000414	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ASMT—malignant glioma	0.000103	0.000413	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOTCH2—malignant glioma	0.000103	0.000412	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CD—malignant glioma	0.000102	0.000408	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	0.000102	0.000408	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KNG1—malignant glioma	0.000101	0.000403	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	9.84e-05	0.000394	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NCOR1—malignant glioma	9.77e-05	0.000391	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—BCAN—malignant glioma	9.7e-05	0.000388	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—BCHE—malignant glioma	9.66e-05	0.000387	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKT2—malignant glioma	9.64e-05	0.000386	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTT1—malignant glioma	9.6e-05	0.000384	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NTRK1—malignant glioma	9.59e-05	0.000384	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SLC5A5—malignant glioma	9.54e-05	0.000382	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CD—malignant glioma	9.27e-05	0.000371	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTGS1—malignant glioma	9e-05	0.00036	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	8.97e-05	0.000359	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP3—malignant glioma	8.92e-05	0.000357	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CB—malignant glioma	8.89e-05	0.000356	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDKN2B—malignant glioma	8.84e-05	0.000354	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTK2—malignant glioma	8.58e-05	0.000344	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CXCL8—malignant glioma	8.55e-05	0.000342	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HES1—malignant glioma	8.43e-05	0.000338	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NCOR1—malignant glioma	8.38e-05	0.000336	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—BCHE—malignant glioma	8.37e-05	0.000335	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—RAF1—malignant glioma	8.27e-05	0.000331	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC5A5—malignant glioma	8.26e-05	0.000331	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—IL2—malignant glioma	8.17e-05	0.000327	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CB—malignant glioma	8.08e-05	0.000323	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDGFRA—malignant glioma	8.03e-05	0.000321	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CAV1—malignant glioma	7.96e-05	0.000319	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—IDH2—malignant glioma	7.82e-05	0.000313	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	7.81e-05	0.000313	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SPP1—malignant glioma	7.79e-05	0.000312	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CXCL8—malignant glioma	7.76e-05	0.000311	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	7.74e-05	0.00031	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTP1—malignant glioma	7.68e-05	0.000308	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CAT—malignant glioma	7.48e-05	0.000299	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL2—malignant glioma	7.42e-05	0.000297	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TERT—malignant glioma	7.39e-05	0.000296	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2B6—malignant glioma	7.35e-05	0.000294	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CG—malignant glioma	7.25e-05	0.00029	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDGFB—malignant glioma	7.21e-05	0.000289	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGFR1—malignant glioma	7.18e-05	0.000287	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HIF1A—malignant glioma	7.07e-05	0.000283	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NCOR1—malignant glioma	7.06e-05	0.000283	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PPARG—malignant glioma	7e-05	0.00028	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CAV1—malignant glioma	6.84e-05	0.000274	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KDR—malignant glioma	6.76e-05	0.000271	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	6.75e-05	0.00027	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—IDH1—malignant glioma	6.72e-05	0.000269	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTP1—malignant glioma	6.66e-05	0.000266	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—F2—malignant glioma	6.51e-05	0.00026	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FN1—malignant glioma	6.51e-05	0.00026	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SPHK1—malignant glioma	6.51e-05	0.00026	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CAT—malignant glioma	6.48e-05	0.000259	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—BAD—malignant glioma	6.43e-05	0.000257	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CD—malignant glioma	6.38e-05	0.000255	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2C18—malignant glioma	6.37e-05	0.000255	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOTCH1—malignant glioma	6.37e-05	0.000255	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CD80—malignant glioma	6.24e-05	0.00025	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CG—malignant glioma	6.23e-05	0.000249	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APC—malignant glioma	6.23e-05	0.000249	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGF—malignant glioma	6.15e-05	0.000246	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NCOR1—malignant glioma	6.12e-05	0.000245	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTPN11—malignant glioma	6.12e-05	0.000245	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—BRAF—malignant glioma	5.85e-05	0.000234	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CAV1—malignant glioma	5.76e-05	0.00023	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT2—malignant glioma	5.7e-05	0.000228	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—EGFR—malignant glioma	5.67e-05	0.000227	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CB—malignant glioma	5.56e-05	0.000223	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTGS2—malignant glioma	5.51e-05	0.00022	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CD—malignant glioma	5.47e-05	0.000219	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CA—malignant glioma	5.42e-05	0.000217	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—KRAS—malignant glioma	5.36e-05	0.000215	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CG—malignant glioma	5.24e-05	0.00021	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGF2—malignant glioma	5.24e-05	0.00021	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTT1—malignant glioma	5.15e-05	0.000206	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PPARG—malignant glioma	5.06e-05	0.000203	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CAV1—malignant glioma	4.99e-05	0.0002	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CA—malignant glioma	4.92e-05	0.000197	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MDM2—malignant glioma	4.9e-05	0.000196	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RAF1—malignant glioma	4.89e-05	0.000196	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ERBB2—malignant glioma	4.83e-05	0.000194	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTGS1—malignant glioma	4.83e-05	0.000193	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTEN—malignant glioma	4.8e-05	0.000192	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CB—malignant glioma	4.77e-05	0.000191	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.76e-05	0.000191	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CD—malignant glioma	4.61e-05	0.000185	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCL8—malignant glioma	4.58e-05	0.000184	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CG—malignant glioma	4.54e-05	0.000182	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—BCHE—malignant glioma	4.49e-05	0.00018	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC5A5—malignant glioma	4.44e-05	0.000178	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKT1—malignant glioma	4.43e-05	0.000177	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CASP3—malignant glioma	4.39e-05	0.000176	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PPARG—malignant glioma	4.38e-05	0.000175	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL2—malignant glioma	4.38e-05	0.000175	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP9—malignant glioma	4.15e-05	0.000166	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTEN—malignant glioma	4.12e-05	0.000165	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKT1—malignant glioma	4.02e-05	0.000161	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CB—malignant glioma	4.02e-05	0.000161	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CD—malignant glioma	3.99e-05	0.00016	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTGS2—malignant glioma	3.98e-05	0.000159	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VEGFA—malignant glioma	3.72e-05	0.000149	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STAT3—malignant glioma	3.69e-05	0.000148	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTP1—malignant glioma	3.57e-05	0.000143	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CB—malignant glioma	3.48e-05	0.000139	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CAT—malignant glioma	3.48e-05	0.000139	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTEN—malignant glioma	3.47e-05	0.000139	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTGS2—malignant glioma	3.45e-05	0.000138	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MYC—malignant glioma	3.43e-05	0.000137	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CA—malignant glioma	3.39e-05	0.000136	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGFR—malignant glioma	3.35e-05	0.000134	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOR1—malignant glioma	3.28e-05	0.000131	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KRAS—malignant glioma	3.17e-05	0.000127	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTEN—malignant glioma	3.01e-05	0.00012	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CA—malignant glioma	2.91e-05	0.000116	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TP53—malignant glioma	2.81e-05	0.000113	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AKT1—malignant glioma	2.77e-05	0.000111	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CAV1—malignant glioma	2.68e-05	0.000107	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CA—malignant glioma	2.45e-05	9.81e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CG—malignant glioma	2.44e-05	9.76e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT1—malignant glioma	2.38e-05	9.51e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPARG—malignant glioma	2.35e-05	9.42e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CD—malignant glioma	2.14e-05	8.58e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CA—malignant glioma	2.12e-05	8.49e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AKT1—malignant glioma	2e-05	8.01e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CB—malignant glioma	1.87e-05	7.48e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTGS2—malignant glioma	1.85e-05	7.41e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKT1—malignant glioma	1.73e-05	6.94e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTEN—malignant glioma	1.61e-05	6.46e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.14e-05	4.56e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKT1—malignant glioma	9.3e-06	3.72e-05	CbGpPWpGaD
